. 2016 Jul 27;10:1385–1399. doi: 10.2147/PPA.S101821

Table 1.

Summary of studies included in the review

Citation	Clinical condition	Preference assessment method	Respondent samples	Comparison of levels within treatment process attributes						Comparison of treatment process attributes to efficacy and safety
Citation	Clinical condition	Preference assessment method	Respondent samples	Route of administration	Dose frequency	Dose timing	Dose size	Treatment duration	Other	Efficacy	Safety
Diabetes studies
Aristides et al⁴¹	Type 2	DCE with WTP	Patients			E1^*				−	+
Bogelund et al²⁰	Type 2	DCE with WTP	Patients	E1^*	E^*	E2^*				+	±
Boye et al³³	Type 2	Utility (SG)	Patients		E^*	NS2					−
Casciano et al³¹	Type 1, Type 2	DCE without WTP	Patients	E1, p = NR	X					±	±
Chancellor et al²⁶	Type 1, Type 2	Utility (TTO)	Patients	E3^*
Evans et al³⁴	Type 1, Type 2	Utility (TTO)	General population and patients		General population sample = E^* Diabetes sample = E^*	General population sample: Basal only regimen = E2^* Basal bolus regimen = E2^* Diabetes sample: Basal only regimen = E2^* Basal bolus regimen = NS
Guimaraes et al²³ (results also reported in Guimaraes et al⁵⁶,⁵⁷)	Type 1, Type 2	DCE with WTP	Patients	E1^* E3^* E4^*						+	+
Hauber et al⁵²	Type 2	DCE with WTP	Patients		Inconclusive: confounded with dose size		Inconclusive: confounded with dose frequency			+	±
Jendle et al²⁵ (results also reported in Jendle et al²⁴)	Type 2	DCE with WTP	Patients	E1^*	E^*					+	±
Lloyd et al³⁶	Type 1, Type 2	DCE with WTP	Patients		E^*					+	−
Mohamed et al⁴²	Type 2	DCE without WTP	Patients				Pills once a day: Swedish sample = NS German sample = NS Pills twice a day: Swedish sample = NS German sample = E^*			+	±
Pinto et al⁵⁸	Type 1, Type 2	Contingent valuation	Patients	NS3
Polster et al⁴⁸	Type 2	DCE without WTP Utility (TTO)	Patients		X	X				+	+
Porzsolt et al⁴⁹	Type 1, Type 2	DCE without WTP	Patients			E2, p = NR				+	+
Sadri²⁷	Not specified	Contingent valuation	General population	E3^*
Sadri et al²⁸	Type 1, Type 2	Contingent valuation	Patients	E3^*
Cancer treatment studies
Aristides et al⁴⁵	Advanced colorectal cancer	DCE with WTP	Proxy (oncology nurses)		NS						+
Bridges et al⁴⁶	Non-small-cell lung cancer	DCE without WTP	Patients	NSS						+	+
Matzaet al¹⁹	Cancer with bone metastases	Utility (TTO)	General population	E2^*				E^*	Renal monitoring blood test = E^*
Shafey et al⁵⁰	Relapsed follicular non-Hodgkins lymphoma	DCE without WTP	Patients	NS7	NS				NS	+	+
Wong et al⁵¹	Renal cell carcinoma	DCE without WTP	Patients	E5^*	NS		NS		Taken with or without food = NS	+	+
Cancer supportive care studies
Langer et al⁴⁷	Solid tumors and anemia	DCE without WTP	Patients and providers (not discussed in current report)						Number of visits = U^*	+
Ossa et al³⁰	Chemotherapy-related anemia	DCE with WTP	General population	E6^* NS8				E^*	Administration in GP office or hospital = E^* Administration in home or hospital = NS	+	+
Sung et al⁵⁹	Febrile neutropenia	DCE without WTP	Patients and parents of patients (not discussed in current report)	Inconclusive: confounded with inpatient/outpatient					Inconclusive: confounded with route of administration
Teuffel et al⁶⁰	Febrile neutropenia	Utility (TTO) Contingent valuation	Patients	NSS					E, p = NR
Autoimmune studies
Augustovski et al³⁸	Rheumatoid arthritis	DCE with WTP	Patients	ES NSI	Every 10 months vs every month = E^* Every 10 months vs every week = E^* Every 10 months vs every day = E^* Every month vs every week = U					±	±
Hauber et al³⁵	Plaque psoriasis	DCE with WTP	Patients	Inconclusive	E^*
Hodgkins et al⁴⁰	Ulcerative colitis	DCE with WTP	Patients		Total sample = E^* Canadian sample = E^* UK sample = E^* German sample = NS US sample = NS		Total sample = E^* Canadian sample = NS UK sample = E^* German sample = NS US sample = E^*			+	+
Lichtenstein et al⁵⁴	Crohn’s disease	DCE without WTP	Patients	X	X				X	±
Ozdemir et al³⁷	Rheumatoid arthritis	DCE with WTP	Patients	Inconclusive	E^*
Schaarschmidt et al⁵³	Psoriasis	DCE with WTP	Patients	X	X			X	Location of treatment = X	±	−
Schaarschmidt et al⁴⁴	Psoriasis	DCE with WTP	Patients	X	X			X	Location of treatment = X
Schmieder et al⁴³	Psoriasis	DCE with WTP	Patients	X	X			X	Location of treatment = X	±	−
Shingler et al⁶	Relapsing remitting MS	DCE without WTP	Patients						Ease of use = E^*
Osteoporosis studies
Darba et al²⁹	Osteoporosis	DCE with WTP	Patients	U1^* E2^*					At home with medical support vs admitted to hospital for administration = E^* Self-administration at home vs administration at home with medical support = E^*
de Bekker-Grob et al²² (results also reported in de Bekker-Grob et al²¹)	Osteoporosis	DCE with WTP	Patients	E1^*	Oral = E^* Injection = X			E^*		±	+
Fraenkel et al³⁹	Osteoporosis	DCE with WTP	Patients	Inconclusive	Inconclusive			Inconclusive		−	−
Silverman et al³²	Osteoporosis	MaxDiff	Patients	E1, p = NR Inconclusive₆ Inconclusive₇	U, p = NR					+	+

Notes:

The preference is statistically significant. NS, the preference is not statistically significant, but there is a preference trend. p = NR, the statistical significance is not reported.

Route of administration: E, expected order of preference was found; U, unexpected order of preference was found; X, preference between levels of route of administration is not presented; blank, route of administration was not examined in this study; I, oral vs injection, 2, injection vs infusion, 3, inhaled vs injection, 4, oral vs inhaled, 5, oral vs infusion, 6, subcutaneous injection vs IV injection, 7, oral vs IV injections, and 8, IV injection vs cannula injection.

Dose frequency: E, expected order of preference was found indicating that less frequency dosing was preferred over more frequent dosing; U, unexpected order of preference was found; X, preference between levels of dose frequency is not presented; blank, dose frequency was not examined in this study.

Dose timing: E, expected order of preference was found; U, unexpected order of preference was found; X, preference between levels of dose timing not presented; blank, dose timing was not examined in this study; I, injecting immediately before meals vs injecting 30–45 minutes before meals, 2, more flexible timing (eg, any time of day) vs less flexible timing (eg, with meals).

Dose size: E, expected order of preference was found indicating that smaller dose size is preferred over a larger dose size; E, fewer tablets preferred over a greater number of tablets; U, unexpected order of preference found; X, preference between levels of dose size is not presented; blank, dose size was not examined in this study.

Treatment duration: E, expected order of preference was found indicating that shorter treatment duration was preferred over longer treatment duration; U, unexpected order of preference was found; X, preference between levels of treatment duration was not presented; blank, treatment duration was not examined in this study.

Other: E, expected order for the indicated attribute was found; U, unexpected order of preference for the indicated attribute was found; X, preference between levels of the indicated attribute was not presented; blank, other treatment process attributes were not examined in this study.

Efficacy: +, efficacy was more important than all treatment process attributes; −, treatment process attributes were more important than efficacy; ±, mixed results; blank, no comparison between treatment process attributes and efficacy.

Safety: +, safety was more important than all treatment process attributes; −, treatment process attributes were more important than safety; ±, mixed results; blank, no comparison between treatment process attributes and safety.

Abbreviations: DCE, discrete-choice experiment; WTP, willingness to pay; TTO, time trade-off; IV, intravenous; GP, general practitioner; MS, multiple sclerosis; SG, standard gamble.